Core Insights - Amarin Corporation presented in vitro data on the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)] oxidation and its potential anti-inflammatory mechanisms at the European Society of Cardiology Congress 2025 [1][2] Mechanisms of Action - The in vitro analyses suggest that EPA may reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) and impact cardiovascular events in at-risk patients with elevated Lp(a) [2][6] - EPA modulates inflammasome activation in monocyte-derived macrophages (MDMs), which may be linked to cardiovascular risk reduction beyond triglyceride lowering [3][5] - Key findings indicate that EPA may reduce extracellular ATP release and caspase 1 activation in stimulated MDMs, providing preliminary evidence of its protective role against inflammation in ASCVD [5][6] Effects on Lipoprotein(a) - Elevated Lp(a) is associated with increased ASCVD risk, and EPA has been shown to inhibit Lp(a) oxidation and its effects on oxidative stress and pro-inflammatory protein expression in endothelial cells [7][8] - The analysis indicates that EPA's lipid-centric scavenging mechanism may inhibit lipoprotein oxidation, thereby reducing its impact on endothelial dysfunction and inflammation [9] Company Overview - Amarin is focused on advancing cardiovascular disease management and increasing scientific understanding of persistent cardiovascular risk beyond traditional therapies [10][11] - VASCEPA (icosapent ethyl) is the first FDA-approved prescription treatment solely comprising this active ingredient, launched in the U.S. in January 2020 for high-risk patients [12][13]